Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms
Findings from this pooled analysis suggest that deucravacitinib may be used in patients with psoriasis to effectively treat both dermatologic and joint symptoms. Graphical abstract available for this article.
Authors
- Matthew J. Colombo (ORCID: https://orcid.org/0009-0006-5653-381X)
- Vibeke Strand (ORCID: https://orcid.org/0000-0003-4978-4072)
- Brandon Becker (ORCID: https://orcid.org/0000-0002-9232-631X)
- Yichen Zhong (ORCID: https://orcid.org/0000-0002-1560-3643)
- April Wang Armstrong (ORCID: https://orcid.org/0000-0003-0064-8707)
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Alice Bendix Gottlieb (ORCID: https://orcid.org/0000-0002-2927-8618)
- Štefan Varga (ORCID: https://orcid.org/0000-0003-1626-1507)
- Androniki Bili (ORCID: https://orcid.org/0000-0002-1455-4288)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Jiyoon Choi (ORCID: https://orcid.org/0009-0008-0948-5717)
- Thomas Lehman (ORCID: https://orcid.org/0000-0001-6588-4212)
Institutions
- University of California, Los Angeles (US)
- Palo Alto University (US)
- Providence College (US)
- University of Washington (US)
- Bristol-Myers Squibb (United States) (US)
- Swedish Medical Center (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of Lübeck (DE)
- Stanford University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1007/s13555-025-01428-9
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Bristol-Myers Squibb